Emergent BioSolutions Inc. (EBS)
USD 8.16
(-7.17%)
USD 8.16
(-7.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -505.29 Million USD | -24.71% |
| 2022 | -32.9 Million USD | -106.69% |
| 2021 | 458.2 Million USD | -6.98% |
| 2020 | 549 Million USD | 144.15% |
| 2019 | 227.3 Million USD | 94.59% |
| 2018 | 152.7 Million USD | -7.05% |
| 2017 | 158.13 Million USD | 17.21% |
| 2016 | 145.06 Million USD | -18.83% |
| 2015 | 177.57 Million USD | 40.39% |
| 2014 | 93.75 Million USD | 50.43% |
| 2013 | 62.32 Million USD | 17.89% |
| 2012 | 43.26 Million USD | 27.21% |
| 2011 | 41.29 Million USD | -48.3% |
| 2010 | 79.35 Million USD | 72.61% |
| 2009 | 46.51 Million USD | 33.98% |
| 2008 | 37.02 Million USD | -7.94% |
| 2007 | 37.91 Million USD | -13.02% |
| 2006 | 43.88 Million USD | -36.15% |
| 2005 | 25.42 Million USD | 518.45% |
| 2004 | 18.7 Million USD | -80.29% |
| 2003 | 55.76 Million USD | 46.61% |
| 2002 | 37.76 Million USD | -16.27% |
| 2001 | 45.3 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -129.69 Million USD | -432.52% |
| 2024 Q1 | 68.6 Million USD | 3722.22% |
| 2023 Q4 | -11.4 Million USD | -3.64% |
| 2023 Q1 | -108.6 Million USD | -574.53% |
| 2023 Q2 | 43.1 Million USD | 139.69% |
| 2023 FY | - USD | -24.71% |
| 2023 Q3 | -11 Million USD | -125.52% |
| 2022 Q4 | -16.1 Million USD | 30.3% |
| 2022 Q2 | -30.5 Million USD | -186.4% |
| 2022 Q3 | -23.1 Million USD | 24.26% |
| 2022 Q1 | 35.3 Million USD | -89.84% |
| 2022 FY | - USD | -106.69% |
| 2021 Q4 | 347.4 Million USD | 1637.17% |
| 2021 FY | - USD | -6.98% |
| 2021 Q1 | 122.4 Million USD | -57.85% |
| 2021 Q2 | 49 Million USD | -59.97% |
| 2021 Q3 | -22.6 Million USD | -146.12% |
| 2020 Q3 | 77.6 Million USD | -50.16% |
| 2020 Q2 | 155.7 Million USD | 904.52% |
| 2020 Q1 | 15.5 Million USD | -85.71% |
| 2020 FY | - USD | 144.15% |
| 2020 Q4 | 290.4 Million USD | 274.23% |
| 2019 Q3 | 96.9 Million USD | 964.84% |
| 2019 FY | - USD | 94.59% |
| 2019 Q1 | -13.7 Million USD | -155.02% |
| 2019 Q2 | 9.1 Million USD | 166.42% |
| 2019 Q4 | 108.5 Million USD | 11.97% |
| 2018 Q2 | 66.82 Million USD | 1998.9% |
| 2018 Q4 | 24.9 Million USD | -28.02% |
| 2018 FY | - USD | -7.05% |
| 2018 Q1 | 3.18 Million USD | -93.97% |
| 2018 Q3 | 34.59 Million USD | -48.24% |
| 2017 Q3 | 58.1 Million USD | 581.53% |
| 2017 FY | - USD | 17.21% |
| 2017 Q1 | 25.74 Million USD | -50.15% |
| 2017 Q2 | 8.52 Million USD | -66.89% |
| 2017 Q4 | 52.8 Million USD | -9.12% |
| 2016 FY | - USD | -18.83% |
| 2016 Q2 | -13.38 Million USD | -175.6% |
| 2016 Q4 | 51.65 Million USD | 45.1% |
| 2016 Q3 | 35.6 Million USD | 366.02% |
| 2016 Q1 | 17.7 Million USD | -64.22% |
| 2015 Q4 | 49.48 Million USD | -20.54% |
| 2015 Q1 | -19.59 Million USD | -136.53% |
| 2015 FY | - USD | 40.39% |
| 2015 Q2 | 29.99 Million USD | 253.06% |
| 2015 Q3 | 62.27 Million USD | 107.61% |
| 2014 Q4 | 53.64 Million USD | 32.46% |
| 2014 FY | - USD | 50.43% |
| 2014 Q2 | 17.67 Million USD | 197.8% |
| 2014 Q1 | -18.07 Million USD | -176.38% |
| 2014 Q3 | 40.5 Million USD | 129.17% |
| 2013 Q2 | 14.74 Million USD | 261.15% |
| 2013 Q3 | 23.46 Million USD | 59.21% |
| 2013 FY | - USD | 17.89% |
| 2013 Q4 | 23.65 Million USD | 0.81% |
| 2013 Q1 | -9.14 Million USD | -137.66% |
| 2012 Q1 | -540 Thousand USD | -101.11% |
| 2012 Q2 | 11.21 Million USD | 2177.41% |
| 2012 Q3 | 12.64 Million USD | 12.69% |
| 2012 FY | - USD | 27.21% |
| 2012 Q4 | 24.28 Million USD | 92.12% |
| 2011 Q1 | -33.23 Million USD | -189.92% |
| 2011 Q3 | 1.43 Million USD | -93.65% |
| 2011 Q2 | 22.51 Million USD | 167.73% |
| 2011 FY | - USD | -48.3% |
| 2011 Q4 | 48.44 Million USD | 3287.62% |
| 2010 Q1 | 4.86 Million USD | -16.66% |
| 2010 Q4 | 36.96 Million USD | 67.88% |
| 2010 FY | - USD | 72.61% |
| 2010 Q3 | 22.01 Million USD | 44.97% |
| 2010 Q2 | 15.18 Million USD | 212.36% |
| 2009 Q3 | -2.35 Million USD | -109.71% |
| 2009 Q2 | 24.26 Million USD | 28.85% |
| 2009 FY | - USD | 33.98% |
| 2009 Q1 | 18.82 Million USD | 711.55% |
| 2009 Q4 | 5.83 Million USD | 347.73% |
| 2008 Q4 | 2.32 Million USD | -86.04% |
| 2008 Q1 | 12.27 Million USD | -72.36% |
| 2008 Q2 | 3.54 Million USD | -71.14% |
| 2008 FY | - USD | -7.94% |
| 2008 Q3 | 16.62 Million USD | 369.47% |
| 2007 Q1 | -4.81 Million USD | -110.61% |
| 2007 Q4 | 44.38 Million USD | 678.57% |
| 2007 Q3 | 5.7 Million USD | 175.77% |
| 2007 Q2 | -7.52 Million USD | -56.42% |
| 2007 FY | - USD | -13.02% |
| 2006 Q1 | 21.94 Million USD | 156.29% |
| 2006 FY | - USD | -36.15% |
| 2006 Q4 | 45.34 Million USD | 2712.15% |
| 2006 Q3 | -1.73 Million USD | -107.91% |
| 2006 Q2 | 21.94 Million USD | 0.0% |
| 2005 Q2 | 28.96 Million USD | 0.0% |
| 2005 Q3 | 28.96 Million USD | 0.0% |
| 2005 FY | - USD | 518.45% |
| 2005 Q1 | 28.96 Million USD | 158.32% |
| 2005 Q4 | -38.98 Million USD | -234.6% |
| 2004 Q3 | 20.87 Million USD | 0.0% |
| 2004 Q2 | 20.87 Million USD | 0.0% |
| 2004 Q4 | -49.66 Million USD | -337.95% |
| 2004 FY | - USD | -80.29% |
| 2004 Q1 | 20.87 Million USD | 0.0% |
| 2003 FY | - USD | 46.61% |
| 2002 FY | - USD | -16.27% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | -65.1 Million USD | -87.61% |
| 2001 Q3 | -34.7 Million USD | 88.15% |
| 2001 Q2 | -292.9 Million USD | -4676.56% |
| 2001 Q1 | 6.4 Million USD | 109.83% |
| 2000 Q4 | -65.1 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 500.78 Million USD | 200.902% |
| Bausch Health Companies Inc. | 2.88 Billion USD | 117.515% |
| Catalent, Inc. | -284 Million USD | -77.923% |
| Elanco Animal Health Incorporated | -224 Million USD | -125.58% |
| Perrigo Company plc | 646.2 Million USD | 178.196% |
| Teva Pharmaceutical Industries Limited | 4.33 Billion USD | 111.662% |
| Zoetis Inc. | 3.68 Billion USD | 113.712% |